20 April 2004
Interferon monotherapy in CCPD patient with chronic hepatitis C: case report
Joanna Konopa, Monika Lichodziejewska-Niemierko, Zofia Michalska, Tomasz Liberek, Bolesław RutkowskiCase Rep Clin Pract Rev 2004; 5(null):209-212 :: ID: 12314
Abstract
Background: Hepatitis C virus (HCV) infection is a serious problem for dialysis patients. Chronic liver disease with symptoms of active hepatitis is a contraindication for renal transplantation as the
disease may progress after transplantation. In addition, treatment of HCV infection after kidney transplantation may increase the risk of graft rejection. Therefore, it is necessary to consider an effective antiviral therapy before transplantation. Optimal dose and time of treatment of peritoneal dialysis patients has not been established.Case Report: 35-year-old woman with chronic renal failure has been treated by continuous cyclic peritoneal dialysis (CCPD). She was planned to be put on the waiting list for renal transplantation. Due to HCV infection interferon-?2a was given as monotherapy at a dose of 6 million units (MU) thrice weekly subcutaneously for five months. After this time reduction of dosage was required because of side effects. Interferon-?2b was administrated as a continuation of therapy at a dose of 3 MU thrice weekly for five consecutive months. The patient became HCV-RNA-PCR negative within 10 months from starting therapy. Fourteen months after cessation of interferon therapy she has still undetectable serum HCV-RNA.Conclusions: This case report documents that administration of IFN-? at 6 MU three times a week for 5 months followed by reduced dose to 50 % for the same time in CCPD patient with hepatitis C was efficient for clearing the serum of HCV-RNA. However, the optimal dose and duration of interferon monotherapy in CCPD patients need to be studied further in a clinical trial on a larger population of patients.
Keywords: HCV infection, Peritoneal Dialysis, Interferon-alpha, Interferon-α
41
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
15 Mar 2024 : Clinical Research
Evaluation of an Optimized Workflow for the Radiofrequency Catheter Ablation of Paroxysmal Atrial FibrillationMed Sci Monit In Press; DOI: 10.12659/MSM.943526
09 May 2024 : Review article
A Review of the Current Status of Disease-Modifying Therapies and Prevention of Alzheimer’s DiseaseMed Sci Monit In Press; DOI: 10.12659/MSM.945091
09 Apr 2024 : Clinical Research
Correlation between Thalamocortical Tract and Default Mode Network with Consciousness Levels in Hypoxic-Isc...Med Sci Monit In Press; DOI: 10.12659/MSM.943802
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952